AI-Enabled Clinical Evaluation Reports (CERs): Ensuring Predictable Costs Year After Year
Maurice Bancsi
23 Jun, 2025
Based in the Netherlands, Maurice has over 27 yearsā experience in the pharmaceutical and biotech industry, mainly supporting pre-approval drugs and biologics for oncology, pulmonary and cardiovascular indications, with extensive experience in developing regulatory strategies, leading cross-functional teams in health authority interactions (Scientific Advice, both on national and EU level) regulatory intelligence and applications including document development to support applications such as MAAs, CTAs, EU & US Orphan Drug Applications, PIPs, iPSPs, IND Annual Reports and DSURs.ā
He holds a Masterās degree in Medical Biology from the University of Utrecht and a Doctorate in Medicines from the University of Leiden, Netherlands.
Other Related Articles
09 Sep, 2026
03 Sep, 2026
Predictable CMC Costs Over Multi-Year Programs: Why Partnership Beats Project-by-Project Outsourcing
03 Sep, 2026
28 Aug, 2026